GH Research Reports Q3 GAAP EPS of -$0.18, Exceeding Analyst Expectations
GH Research (GHRS) reported third-quarter GAAP earnings per share of -$0.18, which outperformed market expectations by $0.13. Despite the net loss, the company maintains a strong liquidity position with $350.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026. The company is currently focused on advancing its pivotal Phase III program for GH001 TRD. Additionally, GH Research is exploring expansion opportunities through U.S.-funded studies into the use of ibogaine for treating Post-Traumatic Stress Disorder (PTSD).
Tickers: $GHRS
Topics: cash position clinical trials earnings beat psychedelics